Sakar Healthcare Reports Q1 FY27 Results: Revenue Rises 38% as Oncology Focus Drives Profitability

Sakar Healthcare Reports Q1 FY27 Results: Revenue Rises 38% as Oncology Focus Drives Profitability​

Sakar Healthcare Limited has released its un-audited financial results for the first quarter of FY27, reporting significant growth in revenue and profitability driven by its expanding oncology portfolio and commitment to vertical integration. The company saw a marked increase in operating margins and is solidifying its transition toward an integrated, regulatory-driven business model.

Financial Highlights (Q1 FY27)​

The financial performance for the quarter reflected strong execution across various segments. Revenue from operations reached ₹ 7,297.25 lakhs, marking a 38% year-on-year (YoY) growth. EBITDA increased by 67% YoY to ₹ 2,124.89 lakhs, yielding an EBITDA margin of 29%. Profit After Tax (PAT) grew by 120% YoY, achieving ₹ 1,028.49 lakhs, which corresponds to a PAT margin of 14%.

The detailed consolidated profit and loss statement for the quarter is presented below:

Operational Strengths and R&D Milestones​

Sakar Healthcare continues to build momentum in its oncology business through both domestic and global engagements, positioning the company for accelerated growth in FY27.

Key operational achievements include:

• Contract & Dossier Management: The company executed over 65 oncology product contracts, with more than 50 commercial discussions currently underway. Globally, Sakar has shared 261 dossiers, of which 178 have been submitted and 16 have received Marketing Authorisations (MAs).
• Regulatory Progress: Sakar completed 26 EU Marketing Authorisation filings, including 15 that were company-owned. Furthermore, the company procured an additional 6 MAs through partners located in Bulgaria and Bosnia.
• Product Development & API Focus: The company has developed 21 APIs in-house, with 16 of these possessing Written Confirmation. Two API’s have received CEP approval, while five more are currently undergoing CEP application processes.
• Technology Transfer: Thirty-three technology transfer projects for oncology products are ongoing with major partners including Accord-Intas, Torrent (UK and Germany), Emcure, Glenmark, and Zydus. Seven of these projects have already secured site variation approvals (two in the UK and five in the EU).
• Global Partnerships: The partnership with Zydus Lifesciences for GCC and other emerging markets marks Sakar’s 40th global anti-cancer product agreement.

Strategic Transformation and Business Model​

Sakar Healthcare is evolving from a traditional contract manufacturer into an API-integrated pharmaceutical organization, specializing in oral solids, injectables, and oncology formulations. The company's status as a vertically integrated player in the global oncology space was cemented by establishing a state-of-the-art oncology facility at Bavla, equipped with integrated API and Finished Dosage (FDF) capabilities.

Sakar operates a diversified business model built on three pillars: CDMO Services, Own Brand Exports, and Licensing/Product Development Technology Transfer. The company currently markets its own branded formulations across more than 60 countries.

The company's pipeline strength is notable, with 55 oncology molecules developed in-house and 32 of these products ready for global launch.

SAKAR Stock Price Movement​

Shares of Sakar Healthcare Limited are gaining momentum in live trading, ticking up 1.33% and reaching ₹841.05 as of 2:05 PM today. The equity has seen 121,106 shares traded during the session, maintaining a strong position within its day's range.